DaVita Inc. (DVA) vs Madrigal Pharmaceuticals, Inc. (MDGL)
A side-by-side comparison of DaVita Inc. and Madrigal Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DVA
DaVita Inc.
$181.72HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
MDGL
Madrigal Pharmaceuticals, Inc.
$497.13HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — DVA vs MDGL
growth of $100 · dividends reinvested · last 10yDVA +169.9% (+10.4%/yr)MDGL +2930.2% (+40.7%/yr)MDGL compounded faster over this window
Log scale — wide-divergence pair
DVA MDGL
DVA vs MDGL: by the numbers
- •DVA is the larger company ($11.67B vs $11.49B market cap).
- •DVA is profitable (6.05% net margin) while MDGL runs a net loss (-25.32%).
Metrics side by side
Valuation
| Metric | DVA | MDGL |
|---|---|---|
| P/E ratio | 15.97 | N/A |
| Forward P/E | 12.30 | N/A |
| PEG ratio | 1.93 | N/A |
| P/S ratio | 0.83 | 8.95 |
| P/B ratio | N/A | 21.93 |
| EV / EBITDA | 7.72 | N/A |
| FCF yield | 13.80% | N/A |
Profitability
| Metric | DVA | MDGL |
|---|---|---|
| Gross margin | 31.02% | 91.48% |
| Operating margin | 15.06% | -25.13% |
| Net margin | 6.05% | -25.32% |
| ROE | N/A | -62.07% |
| ROIC | 11.18% | -37.02% |
Growth (annualized)
| Metric | DVA | MDGL |
|---|---|---|
| Revenue CAGR (5Y) | 3.91% | N/A |
| EPS CAGR (5Y) | 8.25% | N/A |
| FCF CAGR (5Y) | 7.44% | N/A |
| Total return CAGR (5Y) | 9.22% | 44.41% |
Frequently asked
- Is DVA or MDGL more profitable?
- DVA runs the higher net margin — DVA at 6.05% versus MDGL at -25.32%.
- How have DVA and MDGL total returns compared?
- Over the past 10 years, DVA delivered 10.80% and MDGL delivered 41.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
DaVita P/E ratioDaVita ROEMadrigal Pharmaceuticals ROEDaVita operating marginMadrigal Pharmaceuticals operating marginDaVita revenue growthMadrigal Pharmaceuticals revenue growthDaVita free cash flowMadrigal Pharmaceuticals free cash flow
DaVita & Madrigal Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.